New lupus injection passes first safety check in small study
NCT ID NCT06955598
First seen Jan 04, 2026 · Last updated Jun 23, 2026 · Updated 28 times
Summary
This early-phase study tested an experimental drug called SHR-2173 in 30 adults with systemic lupus erythematosus (SLE). The goal was to see if multiple injections under the skin are safe and how the drug moves through the body. Researchers tracked side effects and drug levels in the blood. The study is complete, but results are not yet public.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Renji Hospital affiliated to Shanghai Jiaotong
Shanghai, Shanghai Municipality, 200000, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SHR-2173 (an experimental drug given as injections under the skin)
What this could lead to
If safe and effective, SHR-2173 could offer a new treatment option to help control lupus symptoms and reduce disease activity.
What could go wrong
This is a very early Phase 1 trial with only 30 people, focused on safety and drug levels—not on whether it works. Many early-stage drugs fail in later trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.